Three notes:
1. Most of Merck and Ridgeback Therapeutics’ sales for molnupiravir so far have been concentrated in the U.S., the U.K. and Japan.
2. Merck has delivered 1.4 million courses of the pill to the U.S. since it was authorized in December. The drugmaker is on pace to fulfill its commitment of delivering an additional 3.1 million courses over the next few days.
3. The FDA’s authorization of molnupiravir was more limited than for Pfizer’s antiviral Paxlovid. Molnupiravir is meant for adults who are at high risk of developing severe illness when alternative treatments are “not accessible or clinically appropriate.” A final analysis showed the drug reduced the risk of hospitalization or death among high-risk patients by 30 percent.
Becker’s 3rd Annual Fall Chief Pharmacy Officer Summit is the top tier event that the people leading the future of pharmacy convene. This 3-day event is built specifically for Chief Pharmacy Officers and senior pharmacy leaders. The sessions examine the workforce, financial and clinical priorities shaping pharmacy today. Becker’s is where candid discussions flourish and new ideas thrive. Becker's 3rd Annual Fall Chief Pharmacy Officer Summit
